Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.
Dybul M, Daucher M, Jensen MA, Hallahan CW, Chun TW, Belson M, Hidalgo B, Nickle DC, Yoder C, Metcalf JA, Davey RT, Ehler L, Kress-Rock D, Nies-Kraske E, Liu S, Mullins JI, Fauci AS. Dybul M, et al. Among authors: metcalf ja. J Virol. 2003 Mar;77(5):3229-37. doi: 10.1128/jvi.77.5.3229-3237.2003. J Virol. 2003. PMID: 12584346 Free PMC article. Clinical Trial.
The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.
Migueles SA, Laborico AC, Imamichi H, Shupert WL, Royce C, McLaughlin M, Ehler L, Metcalf J, Liu S, Hallahan CW, Connors M. Migueles SA, et al. J Virol. 2003 Jun;77(12):6889-98. doi: 10.1128/jvi.77.12.6889-6898.2003. J Virol. 2003. PMID: 12768008 Free PMC article.
Diminished proliferation of human immunodeficiency virus-specific CD4+ T cells is associated with diminished interleukin-2 (IL-2) production and is recovered by exogenous IL-2.
Iyasere C, Tilton JC, Johnson AJ, Younes S, Yassine-Diab B, Sekaly RP, Kwok WW, Migueles SA, Laborico AC, Shupert WL, Hallahan CW, Davey RT Jr, Dybul M, Vogel S, Metcalf J, Connors M. Iyasere C, et al. J Virol. 2003 Oct;77(20):10900-9. doi: 10.1128/jvi.77.20.10900-10909.2003. J Virol. 2003. PMID: 14512540 Free PMC article.
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, Herpin B, Perry C, Hallahan CW, Davey RT, Metcalf JA, Connors M, Fauci AS. Dybul M, et al. Among authors: metcalf ja. J Infect Dis. 2002 Jan 1;185(1):61-8. doi: 10.1086/338123. Epub 2001 Dec 14. J Infect Dis. 2002. PMID: 11756982 Clinical Trial.
Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters.
Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS. Dybul M, et al. Among authors: metcalf ja. J Infect Dis. 2003 Aug 1;188(3):388-96. doi: 10.1086/376535. Epub 2003 Jul 10. J Infect Dis. 2003. PMID: 12870120 Clinical Trial.
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
Dybul M, Nies-Kraske E, Dewar R, Maldarelli F, Hallahan CW, Daucher M, Piscitelli SC, Ehler L, Weigand A, Palmer S, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Beck I, Frenkel L, Baseler M, Coffin J, Fauci AS. Dybul M, et al. Among authors: metcalf ja. J Infect Dis. 2004 Jun 1;189(11):1974-82. doi: 10.1086/386344. Epub 2004 May 10. J Infect Dis. 2004. PMID: 15143462 Clinical Trial.
Naïve T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion.
Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R, Yoder C, Jones E, Chow C, Metcalf JA, Sidorov IA, Dimitrov DS, Polis MA, Kovacs JA. Di Mascio M, et al. Among authors: metcalf ja. J Virol. 2006 Mar;80(6):2665-74. doi: 10.1128/JVI.80.6.2665-2674.2006. J Virol. 2006. PMID: 16501076 Free PMC article.
Diminished production of monocyte proinflammatory cytokines during human immunodeficiency virus viremia is mediated by type I interferons.
Tilton JC, Johnson AJ, Luskin MR, Manion MM, Yang J, Adelsberger JW, Lempicki RA, Hallahan CW, McLaughlin M, Mican JM, Metcalf JA, Iyasere C, Connors M. Tilton JC, et al. Among authors: metcalf ja. J Virol. 2006 Dec;80(23):11486-97. doi: 10.1128/JVI.00324-06. Epub 2006 Sep 27. J Virol. 2006. PMID: 17005663 Free PMC article.
Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load.
Tilton JC, Luskin MR, Johnson AJ, Manion M, Hallahan CW, Metcalf JA, McLaughlin M, Davey RT Jr, Connors M. Tilton JC, et al. Among authors: metcalf ja. J Virol. 2007 Mar;81(6):2713-25. doi: 10.1128/JVI.01830-06. Epub 2006 Dec 20. J Virol. 2007. PMID: 17182676 Free PMC article.
Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells.
Daucher M, Price DA, Brenchley JM, Lamoreaux L, Metcalf JA, Rehm C, Nies-Kraske E, Urban E, Yoder C, Rock D, Gumkowski J, Betts MR, Dybul MR, Douek DC. Daucher M, et al. Among authors: metcalf ja. J Virol. 2008 Apr;82(8):4102-14. doi: 10.1128/JVI.02212-07. Epub 2008 Jan 30. J Virol. 2008. PMID: 18234797 Free PMC article.
191 results